The patients were divided into four types according to the HR and HER2 status of preoperative biopsy: 107 patients (42.1%) had HR + /HER2- breast cancer, 46 patients (18.1%) had HR + /HER2 + breast cancer,53 patients (20.9%) had HR-/HER2 + breast cancer, and 48 patients (18.9%) had TNBC( as shown in Table 1). This evidence concerns the gene ERBB2 and breast cancer.